Advertisement
Research Article

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

  • Surender Khurana,

    Affiliation: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America

    X
  • Amorsolo L. Suguitan Jr.,

    Affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Yonaira Rivera,

    Affiliation: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America

    X
  • Cameron P. Simmons,

    Affiliation: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

    X
  • Antonio Lanzavecchia,

    Affiliation: Institute for Research in Biomedicine, Bellinzona, Switzerland

    X
  • Federica Sallusto,

    Affiliation: Institute for Research in Biomedicine, Bellinzona, Switzerland

    X
  • Jody Manischewitz,

    Affiliation: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America

    X
  • Lisa R. King,

    Affiliation: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America

    X
  • Kanta Subbarao,

    Affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Hana Golding mail

    hana.golding@fda.hhs.gov

    Affiliation: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America

    X
  • Published: April 21, 2009
  • DOI: 10.1371/journal.pmed.1000049

About the Authors

Surender Khurana, Yonaira Rivera, Jody Manischewitz, Lisa R. King, Hana Golding
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, Maryland, United States of America
Amorsolo L. Suguitan Jr., Kanta Subbarao
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Cameron P. Simmons
Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Antonio Lanzavecchia, Federica Sallusto
Institute for Research in Biomedicine, Bellinzona, Switzerland

Corresponding Author

Email: hana.golding@fda.hhs.gov

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

ICMJE criteria for authorship read and met: SK ALS YR CPS AL FS JM LRK KS HG. Agree with the manuscript’s results and conclusions: SK ALS YR CPS AL FS JM LRK KS HG. Designed the experiments/the study: SK CPS KS HG. Analyzed the data: SK ALS YR CPS HG. Collected data/did experiments for the study: SK ALS YR JM LRK. Wrote the first draft of the paper: SK HG. Contributed to the writing of the paper: SK ALS CPS AL KS HG. Conducted virus neutralization assays involving H5N1 wild-type virus and performed preliminary work on evaluating the efficiency of synthetic peptides to block the neutralizing activity of H5 HA-specific hMAbs: ALS. Provided reagents: AL. Supervised the work done at IRB and provided human monoclonal antibodies: FS. Performed the microneutralization assay and analyzed the data from the assays: JM LRK. Designed some of the experiments: KS.